QurAlis to Participate in Upcoming Investor Conferences in September: CEO Kasper Roet to Present at Citi, Wells Fargo, Morgan Stanley, and More

QurAlis Corporation, a clinical-stage biotech company, announced that CEO Kasper Roet will participate in several investor conferences in September, including the Citi 2025 Back to School Summit, Wells Fargo Securities Healthcare Conference, Morgan Stanley Annual Global Healthcare Conference, TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit, and Bank of America Healthcare Trailblazers Private Company Showcase Conference. Management will also participate in one-on-one investor meetings. The QurAlis corporate presentation can be accessed on the company's website.

Fennec Pharmaceuticals, a commercial-stage biotechnology company focused on improving cancer treatment outcomes, reported significant quarterly revenue growth in Q2 2025. The company's revenue increased by 33% year-over-year, marking its highest quarterly net product sales to date [1].

Fennec's success can be attributed to the robust performance of its flagship product, PEDMARK®. This FDA-approved medication is designed to reduce the risk of ototoxicity (hearing loss) from cisplatin in pediatric patients. The unique formulation of sodium thiosulfate in PEDMARK® has proven effective in protecting young patients from this common complication of cisplatin therapy [1].

The company has also made significant strides in expanding its market presence. In Europe, PEDMARQSI®, the branded version of PEDMARK®, received approval from the European Medicines Agency (EMA) in June 2023 and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) in October 2023. Fennec has secured an exclusive licensing agreement with Norgine to commercialize PEDMARQSI® in Europe, Australia, and New Zealand, with potential milestone payments and tiered royalties up to $230 million [1].

The company's strategic initiatives have led to initial uptake in the UK and Germany, with additional European rollouts planned. PEDMARQSI® has been recommended for reimbursement by the National Institute for Health and Care Excellence (NICE) and accepted by the Scottish Medicines Consortium, indicating strong market potential [1].

Fennec Pharmaceuticals is also actively pursuing opportunities in Japan. The STS-J01 trial, which is expected to read out in the second half of 2025, could pave the way for potential partnerships or licensing deals to monetize the results [1].

The company's intellectual property portfolio is robust, with U.S. Orange Book patents providing protection until 2039 and 7 years of market exclusivity under Orphan Drug designation. Additionally, Fennec holds a Pediatric-use Marketing Authorization (PUMA) in the EU with 10 years of exclusivity [1].

Fennec's corporate presentation, available on the company's website, provides detailed insights into these developments and the company's strategic vision for the future.

References:
[1] Fennec Pharmaceuticals Corporate Presentation, August 2025, https://www.fennecpharma.com